nach oben

International Ophthalmology

Erschienen in:

01.12.2024 | Review

Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives

verfasst von: Pradip Nirbhavane, Gajanand Sharma, Rajeev Sharma, O. P. Katare

Erschienen in: International Ophthalmology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Intraocular inflammation, commonly referred to as uveitis, is a prevalent ocular disease. The categorization of uveitis may be based on the prevailing anatomical site, which includes anterior, intermediate, and posterior uveitis. There exists a significant body of evidence indicating that T cells play a pivotal role in the pathogenesis of autoimmune uveitis. In addition to the presence of T cells, an elevation in levels of inflammatory cytokines and a reduction in regulatory cytokines were also noted.

Main body of the abstract

The primary pharmacological interventions for uveitis comprise of corticosteroids, methotrexate, anti-vascular endothelial growth factor (VEGF) agents, anti-tumor necrosis factor-alpha (TNF-α) antibodies, and sirolimus. These medications offer prompt alleviation for inflammation. Nevertheless, prolonged administration of corticosteroids invariably leads to unfavorable adverse reactions. The traditional topical corticosteroids exhibit certain limitations, including inadequate transcorneal permeation and low corneal retention, leading to reduced ocular bioavailability. Consequently, there is a growing inclination towards the creation of innovative steroid drug delivery systems with the aim of reducing the potential for adverse effects, while simultaneously enhancing the drug's corneal permeation and retention.

Conclusion

This review is an attempt to compile all the research work done so far in this field and provides a brief overview of the global efforts to develop innovative nanocarrier-based systems for corticosteroids.

Pepple KL, Rotkis L, Wilson L, Sandt A, Van Gelder RN (2015) Comparative proteomic analysis of two uveitis models in lewis rats. Invest Ophthalmol Vis Sci 56:8449–8456. https://doi.org/10.1167/iovs.15-17524CrossRefPubMedPubMedCentral

Tallouzi MO, Moore DJ, Calvert M, Murray PI, Bucknall N, Denniston AK (2016) The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol. Syst Rev 5:1–7. https://doi.org/10.1186/s13643-016-0203-yCrossRef

Damato EM, Dawson S, Liu X et al (2017) A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis. J Ophthalmic Inflamm Infect 7:1–6. https://doi.org/10.1186/s12348-017-0141-4CrossRef

Suresh PK, Sah AK (2014) Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. Expert Opin Drug Deliv 11:1747–1768. https://doi.org/10.1517/17425247.2014.938045CrossRefPubMed

Read RW (2006) Uveitis: advances in understanding of pathogenesis and treatment. Curr Rheumatol Rep 8:260–266. https://doi.org/10.1007/s11926-006-0006-6CrossRefPubMed

Wu X, Tao M, Zhu L, Zhang T, Zhang M (2022) Pathogenesis and current therapies for non- infectious uveitis. Clin Exp Med 2022:1–18. https://doi.org/10.1007/S10238-022-00954-6CrossRef

Mustafa M, Muthusamy P, Hussain SS, Shimmi SC, Sein MM (2014) Uveitis: pathogenesis, clinical presentations and treatment. J Pharm 4:42–47. https://doi.org/10.9790/3013-0401201042047CrossRef

Shao H, Liao T, Ke Y, Shi H, Kaplan HJ, Sun D (2006) Severe chronic experimental autoimmune uveitis (EAU) of the C57BL/6 mouse induced by adoptive transfer of IRBP1-20- specific T cells. Exp Eye Res 82:323–331. https://doi.org/10.1016/j.exer.2005.07.008CrossRefPubMed

Shao H, Lei S, Sun S, Kaplan HJ, Sun D (2003) Conversion of monophasic to recurrent autoimmune disease by autoreactive T cell subsets. J Immunol 171:5624–30. https://doi.org/10.4049/jimmunol.171.10.5624CrossRefPubMed

10.

Guo D, Li J, Liu Z, Tang K, Song H, Bi H (2015) Characterization of microRNA expression profiling in peripheral blood lymphocytes in rats with experimental autoimmune uveitis. Inflamm Res 64:683–696. https://doi.org/10.1007/s00011-015-0848-3CrossRefPubMed

11.

Janssens S, Beyaert R (2003) Role of toll-like receptors in pathogen recognition. Clin Microbiol Rev 16:637–646. https://doi.org/10.1128/CMR.16.4.637-646.2003CrossRefPubMedPubMedCentral

12.

Uchida T, Honjos M, Yamagishi R, Aihara M (2017) The anti-inflammatory effect of ripasudil (K-115), a Rho kinase (ROCK) inhibitor, on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 58:5584–5593. https://doi.org/10.1167/iovs.17-22679CrossRefPubMed

13.

Chan CC (1998) Immunopathology of uveitis. Br J Ophthalmol 82:91–96. https://doi.org/10.1136/bjo.82.1.91CrossRefPubMedPubMedCentral

14.

Soriano A, Soriano M, Oliva R, Smith WM (2022) Uveitis: insights into pathogenesis treatment. Front Med 9:3420. https://doi.org/10.3389/FMED.2022.1033817/BIBTEXCrossRef

15.

Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513. https://doi.org/10.1016/S0002-9394(00)00659-0CrossRefPubMed

16.

Agrawal R, Lee C, Phatak S, Pavesio C (2014) Immunopharmacotherapy of non-infectious uveitis: where do we stand? Expert Opin Biol Ther 14:1719–1722. https://doi.org/10.1517/14712598.2014.963049CrossRefPubMedPubMedCentral

17.

Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. Nat Biomed Eng 5:951–967. https://doi.org/10.1038/S41551-0216698wCrossRefPubMed

18.

Baryakova TH, Pogostin BH, Langer R, McHugh KJ (2023) Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov 22:387–409. https://doi.org/10.1038/S41573-023-00670-0CrossRefPubMedPubMedCentral

19.

Ghadiri N, Reekie IR, Gordon I, Safi S, Lingham G, Evans JR et al (2023) Systematic review of clinical practice guidelines for uveitis. BMJ Open Ophthalmol 8:1–12. https://doi.org/10.1136/BMJOPHTH-2022-001091CrossRef

20.

Abdulla D, Ali Y, Menezo V, Taylor SRJ (2022) The use of sustained release intravitreal steroid implants in non-infectious uveitis affecting the posterior segment of the eye. Ophthalmol Ther 11:479. https://doi.org/10.1007/S40123-022-00456-4CrossRefPubMedPubMedCentral

21.

McHarg M, Young LA, Kesav N, Yakin M, Sen HN, Kodati S (2022) Practice patterns regarding regional corticosteroid treatment in noninfectious uveitis: a survey study. J Ophthalmic Inflamm Infect 12:1–7. https://doi.org/10.1186/S12348-021-00281-Z/TABLES/1CrossRef

22.

Pohlmann D, vom Brocke GA, Winterhalter S, Steurer T, Thees S, Pleyer U (2018) Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology 125:1088–1099. https://doi.org/10.1016/j.ophtha.2017.12.038CrossRefPubMed

23.

Goldstein DA, Do D, Noronha G, Kissner JM, Srivastava SK, Nguyen QD (2016) Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Trans Vis Sci Technol 5:1–8. https://doi.org/10.1167/tvst.5.6.14CrossRef

24.

Sheppard JD, Foster CS, Toyos MM, Markwardt K, Da Vanzo R, Flynn TE et al (2019) Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: pooled efficacy analysis of two phase 3 studies. Ocul Immunol Inflamm 27:484–96. https://doi.org/10.1080/09273948.2017.1407433CrossRefPubMed

25.

O’Neil EC, Huang J, Suhler EB, Dunn JP, Perez VL, Gritz DC et al (2018) Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311610CrossRefPubMed

26.

Errera MH, Westcott M, Benesty J, Falah S, Smadja J, Orès R et al (2019) A comparison of the dexamethasone implant (Ozurdex®) and inferior fornix-based sub-tenon triamcinolone acetonide for treatment of inflammatory ocular diseases. Ocul Immunol Inflamm 27:319–329. https://doi.org/10.1080/09273948.2018.1501492CrossRefPubMed

27.

Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN et al (2015) Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology 122:2351–2359. https://doi.org/10.1016/j.ophtha.2015.07.036CrossRefPubMed

28.

Papangkorn K, Truett KR, Vitale AT, Jhaveri C, Scales DK, Foster CS et al (2019) Novel dexamethasone sodium phosphate treatment (DSP-visulex) for noninfectious anterior uveitis: a randomized phase I/II clinical trial. Curr Eye Res 44:185–193. https://doi.org/10.1080/02713683.2018.1540707CrossRefPubMed

29.

Khoramnia R, Peto T, Koch F, Taylor SR, de Sousa JPC, Hill L (2022) Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol 2022:1–7. https://doi.org/10.1136/BJO-2022-321415CrossRef

30.

Nguyen D. Multicenter study on the efficacy and safety of OCS-01 in subjects with uveitis related and post surgical macular edema-full text view-ClinicalTrials.gov, (n.d.)

31.

Onugwu AL, Nwagwu CS, Onugwu OS, Echezona AC, Agbo CP, Ihim SA et al (2023) Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release 354:465–488. https://doi.org/10.1016/J.JCONREL.2023.01.018CrossRefPubMed

32.

LuoNagai N, Otake H (2022) Novel drug delivery systems for the management of dry eye. Adv Drug Deliv Rev 191:114582. https://doi.org/10.1016/J.ADDR.2022.114582CrossRef

33.

Bravo-Osuna L, Jesús M, Sanjuán R, Tsung TH, Chen YH, Lu DW (2023) Updates on biodegradable formulations for ocular drug delivery. Pharmaceutics 15:734. https://doi.org/10.3390/PHARMACEUTICS15030734CrossRef

34.

Ahmed S, Amin MM, Sayed S (2023) Ocular drug delivery: a comprehensive review. AAPS PharmSciTech 24:1–29. https://doi.org/10.1208/S12249-023-02516-9CrossRef

35.

Han H, Li S, Xu M, Zhong Y, Fan W, Xu J et al (2023) Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives. Adv Drug Deliv Rev 196:114770. https://doi.org/10.1016/j.addr.2023.114770CrossRefPubMed

36.

Luo L, Yang J, Oh Y, Hartsock MJ, Xia S, Kim YC et al (2019) Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. J Control Release 28:68–80. https://doi.org/10.1016/j.jconrel.2019.01.018CrossRef

37.

Huang J, Yu X, Zhou Y, Zhang R, Song Q, Wang Q et al (2018) Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation. Int J Pharm 551:223–231. https://doi.org/10.1016/j.ijpharm.2018.09.015CrossRefPubMed

38.

Dibkia K, Omidi Y, Siahi MR et al (2007) Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther 23:421–32. https://doi.org/10.1089/jop.2007.0039CrossRef

39.

Sabzevari A, Adibkia K, Hashemi H, Javadzadeh AR, Barzegar-Jalali M, Barar J et al (2013) Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: In vitro and in vivo studies. Eur J Pharm Biopharm 84:63–71. https://doi.org/10.1016/j.ejpb.2012.12.010CrossRefPubMed

40.

Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J et al (2022) Dexamethasone: insights into pharmacological aspects. Therap Mech Deliv Syst ACS Biomater Sci Eng 8:1763–1790. https://doi.org/10.1021/ACSBIOMATERIALS.2C00026/ASSET/IMAGES/LARGE/AB2C00026_0009.JPEGCrossRef

41.

Deshmukh AS, Chauhan PN, Noolvi MN, Chaturvedi K, Ganguly K, Shukla SS et al (2017) Polymeric micelles: basic research to clinical practice. Int J Pharm 532:249–268. https://doi.org/10.1016/j.ijpharm.2017.09.005CrossRefPubMed

42.

Cagel M, Tesan FC, Bernabeu E, Salgueiro MJ, Zubillaga MB, Moretton MA et al (2017) Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur J Pharm Biopharm 113:211–228. https://doi.org/10.1016/j.ejpb.2016.12.019CrossRefPubMed

43.

Kaushal N, Kumar M, Singh A, Tiwari A, Tiwari A, Pahwa R (2022) A review on polymeric nanostructured micelles for the ocular inflammation-main emphasis on uveitis. Pharm Nanotechnol 11:34–43. https://doi.org/10.2174/2211738511666221019160908CrossRef

44.

Li Z, Liu M, Ke L, Wang LJ, Wu C, Li C et al (2021) Flexible polymeric nanosized micelles for ophthalmic drug delivery: research progress in the last three years. Nanoscale Adv 3:5240–5254. https://doi.org/10.1039/D1NA00596KADSCrossRefPubMedPubMedCentral

45.

Safwat MA, Mansour HF, Hussein AK, Abdelwahab S, Soliman GM et al (2020) Polymeric micelles for the ocular delivery of triamcinolone acetonide: preparation and in vivo evaluation in a rabbit ocular inflammatory model. Drug Deliv 27:1115. https://doi.org/10.1080/10717544.2020.1797241CrossRefPubMedPubMedCentral

46.

Rafie F, Javadzadeh Y, Javadzadeh AR, Ghavidel LA, Jafari B, Moogooee M et al (2010) In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye. Curr Eye Res 35:1081–1089. https://doi.org/10.3109/02713683.2010.508867CrossRefPubMed

47.

Alshamsan A, Abul Kalam M, Reza Vakili M, Binkhathlan Z, Raish M, Ali R et al (2019) Treatment of endotoxin-induced uveitis by topical application of cyclosporine a-loaded PolyGelTM in rabbit eyes. Int J Pharm 569:118573. https://doi.org/10.1016/j.ijpharm.2019.118573CrossRefPubMed

48.

Ghezzi M, Ferraboschi I, Delledonne A, Pescina S, Padula C, Santi P et al (2022) Cyclosporine-loaded micelles for ocular delivery: investigating the penetration mechanisms. J Control Release 349:744–755. https://doi.org/10.1016/J.JCONREL.2022.07.019CrossRefPubMed

49.

Reijerkerk A, Appeldoorn CCM, Rip J, de Boer M, Gaillard PJ (2014) Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation. Invest Ophthalmol Vis Sci 55:2788–2794. https://doi.org/10.1167/iovs.13-13599CrossRefPubMed

50.

Wong CW, Czarny B, Metselaar JM, Ho C, Ng SR, Barathi AV et al (2018) Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Sci Rep 8:6604. https://doi.org/10.1038/s41598-018-24545-2ADSCrossRefPubMedPubMedCentral

51.

Wissing SA, Müller RH (2003) Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 254:65–68. https://doi.org/10.1016/S0378-5173(02)00684-1CrossRefPubMed

52.

da Ana R, Fonseca J, Karczewski J, Silva AM, Zielińska A, Souto EB (2022) Lipid-based nanoparticulate systems for the ocular delivery of bioactives with anti-inflammatory properties. Int J Mol Sci 23:12102. https://doi.org/10.3390/ijms232012102CrossRefPubMedPubMedCentral

53.

Chen YC, Liu DZ, Liu JJ, Chang TW, Ho HO, Sheu MT (2012) Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomed 7:4409–4418. https://doi.org/10.2147/IJN.S33682CrossRef

54.

Gugleva V, Andonova V (2023) Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms. Pharmaceuticals 16:474. https://doi.org/10.3390/ph16030474CrossRefPubMedPubMedCentral

55.

Ban J, Zhang Y, Huang X, Deng G, Hou D, Chen Y et al (2017) Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone. Int J Nanomed 12:1329–1339. https://doi.org/10.2147/IJN.S126199CrossRef

56.

Mo Z, Ban J, Zhang Y, Du Y, Wen Y, Huang X et al (2018) Nanostructured lipid carriers-based thermosensitive eye drops for enhanced, sustained delivery of dexamethasone. Nanomedicine 13:1239–1253. https://doi.org/10.2217/nnm-2017-0318CrossRefPubMed

57.

Sankhyan A, Pawar P (2012) Recent trends in niosome as vesicular drug delivery system. J Appl Pharm Sci 7:5423–5436. https://doi.org/10.7324/JAPS.2012.2625CrossRef

58.

Verma A, Tiwari A, Saraf S, Panda PK, Jain A, Jain SK (2021) Emerging potential of niosomes in ocular delivery. Expert Opin Drug Deliv 18:55–71. https://doi.org/10.1080/17425247.2020.1822322CrossRefPubMed

59.

Abdelkader H, Alani AWG, Alany RG (2014) Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 21:87–100. https://doi.org/10.3109/10717544.2013.838077CrossRefPubMed

60.

Gaafar PME, Abdallah OY, Farid RM, Abdelkader H (2014) Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone. J Liposome Res 24:204–215. https://doi.org/10.3109/08982104.2014.881850CrossRefPubMed

61.

Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL et al (2010) Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin 31:990–998. https://doi.org/10.1038/aps.2010.98CrossRefPubMedPubMedCentral

62.

Younes NF, Abdel-Halim SA, Elassasy AI (2018) Corneal targeted sertaconazole nitrate loaded cubosomes: preparation, statistical optimization, in vitro characterization, ex vivo permeation and in vivo studies. Int J Pharm 553:386–397. https://doi.org/10.1016/j.ijpharm.2018.10.057CrossRefPubMed

63.

Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X et al (2010) Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm 396:179–187. https://doi.org/10.1016/j.ijpharm.2010.06.015CrossRefPubMed

64.

Gaballa SA, El Garhy OH, Moharram H, Abdelkader H (2020) Preparation and evaluation of cubosomes/cubosomal gels for ocular delivery of beclomethasone dipropionate for management of uveitis. Pharm Res. 37:1–23. https://doi.org/10.1007/S11095-020-02857-1CrossRef

65.

Zvonar A, Berginc K, Kristl A, Gašperlin M (2010) Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Int J Pharm 388:151–158. https://doi.org/10.1016/j.ijpharm.2009.12.055CrossRefPubMed

66.

Cai S, Shi CH, Zhang X, Tang X, Suo H, Yang L et al (2014) Self-micro emulsifying drug- delivery system for improved oral bioavailability of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol: preparation and evaluation. Int J Nanomed 12:913–20. https://doi.org/10.2147/IJN.S56894CrossRef

67.

Tiwari R, Dubey V, Kesavan K (2019) Ocular self-microemulsifying drug delivery system of prednisolone improves therapeutic effectiveness in the treatment of experimental uveitis. Ocul Immunol Inflamm 27:303–311. https://doi.org/10.1080/09273948.2017.1333622CrossRefPubMed

68.

Bashmakov YK, Petyaev IM (2017) Dendrimers Carotenoids, and Monoclonal Antibodies. Monoclon Antib Immunodiagn Immunother 36:208–213. https://doi.org/10.3390/molecules22091401CrossRefPubMed

69.

Caminade AM, Turrin CO, Poupot R (2022) Curing inflammatory diseases using phosphorous dendrimers. Wiley Interdiscip Rev Nanomed Nanobiotechnol 14:e1783. https://doi.org/10.1089/mab.2017.0032.10.1002/WNAN.1783CrossRefPubMed

70.

Choksi A, Sarojini KVL, Vadnal P, Dias C, Suresh PK, Khandare J (2013) Comparative anti- inflammatory activity of poly(amidoamine) (PAMAM) dendrimer-dexamethasone conjugates with dexamethasone-liposomes. Int J Pharm 449:28–36. https://doi.org/10.1016/j.ijpharm.2013.03.056CrossRefPubMed

71.

Barcia E, Herrero-Vanrell R, Díez A, Alvarez-Santiago C, López I, Calonge M (2009) Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res 89:238–245CrossRefPubMed

72.

Yu X, Zhang R, Lei L, Song Q, Li X (2019) High drug payload nanoparticles formed from dexamethasone-peptide conjugates for the treatment of endotoxin-induced uveitis in rabbit. Int J Nanomed 14:591–603. https://doi.org/10.1016/j.exer.2009.03.012CrossRef

73.

Katzer T, Chaves P, Bernardi A, Pohlmann A, Guterres SS, Ruver Beck RC (2014) Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. J Microencapsul 31:519–528. https://doi.org/10.2147/IJN.S179118CrossRefPubMed

74.

Bongiovì F, Di Prima G, Palumbo FS, Licciardi M, Pitarresi G, Giammona G (2017) Hyaluronic acid-based micelles as ocular platform to modulate the loading, release, and corneal permeation of corticosteroids. Macromol Biosci 17:1700261. https://doi.org/10.3109/02652048.2013.879930CrossRef

75.

Chennamaneni SR, Mamalis C, Archer B, Oakey Z, Ambati BK (2013) Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation. J Control Release 167:53–59. https://doi.org/10.1002/mabi.201700261CrossRefPubMedPubMedCentral

76.

Mendes LP, Pan J, Torchilin VP (2017) Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22:1–21. https://doi.org/10.1080/09273948.2017.1333622CrossRef

77.

Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H (2011) Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experiWongmental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 52:1526–1531. https://doi.org/10.1016/j.jconrel.2013.01.007CrossRef

78.

Yang X, Trinh HM, Agrahari V, Sheng Y, Pal D, Mitra AK (2016) Nanoparticle-based topical ophthalmic gel formulation for sustained release of hydrocortisone butyrate. AAPS PharmSciTech 17:294–306. https://doi.org/10.1167/iovs.10-5676CrossRefPubMed

79.

Feghhi M, Sharif B, Farrahi F, Sharafi A, Kasiri A (2021) Development of nano-formulating dexamethasone for anterior uveitis treatment: a randomized clinical trial study. Med Sci 25:2440–2451. https://doi.org/10.1208/s12249-015-0354-5CrossRef

80.

Zashikhina N, Gladnev S, Sharoyko V, Korzhikov-Vlakh V, Korzhikov-Vlakh E, Tennikova T (2023) Synthesis and characterization of nanoparticle-based dexamethasone-polypeptide conjugates as potential intravitreal delivery systems. Int J Mol Sci 24:3702. https://doi.org/10.3390/IJMS24043702/S1CrossRefPubMedPubMedCentral

81.

Formica ML, Awde Alfonso HG, Paredes AJ, Melian ME, Camacho NM, Faccio R et al (2023) Development of triamcinolone acetonide nanocrystals for ocular administration. Pharmaceutics 15:683. https://doi.org/10.3390/pharmaceutics15020683CrossRefPubMedPubMedCentral

82.

Nirbhavane P, Sharma G, Singh B, Begum B, Jones MC, Rauz S et al (2020) Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis: evidences of improved bio-pharmaceutical performance and anti-inflammatory activity. Colloids Surf B 190:110902. https://doi.org/10.1016/j.colsurfb.2020.110902CrossRef

83.

Nirbhavane P, Moksha L, Sharma G, Velpandian T, Singh B, Katare OP (2023) Cationic nano-lipidic carrier mediated ocular delivery of Triamcinolone acetonide: a preclinical investigation in the management of uveitis. Life 13:1057. https://doi.org/10.3390/life13041057ADSCrossRefPubMedPubMedCentral

84.

Tatke A, Dudhipala N, Janga KY, Balguri SP, Avula B (2019) In situ gel of triamcinolone acetonide-loaded solid lipid nanopar nanoparticles for impr ticles for improved topical ocular deliv opical ocular delivery: tear kinetics ear kinetics and ocular disposition studies. Nanomaterials 9:1–19. https://doi.org/10.3390/nano9010033CrossRef

85.

Kaushal N, Kumar M, Tiwari A, Tiwari A, Sharma K, Sharma A et al (2023) Polymeric micelles loaded in situ gel with prednisolone acetate for ocular inflammation: development and evaluation. Nanomedicine 13:1–10. https://doi.org/10.2217/nnm-2023-0123CrossRef

86.

Stefansson LTE (2017) Cyclodextrin nanotechnology for ophthalmic drug delivery cyclodextrin. Patent No. EP1909755 B1

87.

Lavik E, Young H, Kuehn M, Kuehn M, Kwon YH, Robinson R, et al (2008) Sustained intraocular delivery of drugs from biodegradable polymerc microparticles. Patent No. US 8492334 B2

88.

Huang GT, Nivaggioli T, Spada LT, Sugimoto H, Blanda WM, Chang JN et al (2014) Methods of treating ocular disease using steroid-containing sustained release intraocular implants Inventors. Patent No. US8771722B2

89.

Huang GT, Nivaggioli T, Spada LT, Sugimoto H, Blanda WM, Chang JN et al (2014) Steroid-containing sustained release intraocular implants and related methods. Patent No. US 8802128 B2

90.

Zarnitsyn V, Patel S, White D, Noronha G, Burke B (2018) Methods and devices for the treatment of ocular diseases in human subjects. Patent No. US9636332 B2

91.

Bar-Shalom D, Skode JS (2011) Liposome system for ocular administration field

92.

Noronha G, John Brooks C, Andino RV, Patel S, White D (2018) Methods and devices for treating posterior ocular disorders. Patent no. W02011098578A2

93.

Raut R (XXXX) Ophthalmic pharmaceutical compositions and methods for treating ocular US 2006/001478.6A1

94.

Xia E (2019) Ophthalmic pharmaceutical compositions and uses thereof. Patent no. US2004/0224010 A1

Titel: Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives
verfasst von: Pradip Nirbhavane
Gajanand Sharma
Rajeev Sharma
O. P. Katare
Publikationsdatum: 01.12.2024
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 1/2024
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-03000-4

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives

Abstract

Background

Main body of the abstract

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Main body of the abstract

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Evaluation of dry eye disease and corneal epithelial mapping in patients with lower eyelid ectropion

Thickness of anterior sclera and corneal layers in systemic sclerosis

Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves’ orbitopathy

Functional and perfusion changes associated with silicone oil tamponade after macula-off rhegmatogenous retinal detachment surgery: an optical coherence tomography angiography/microperimetry study

The effects of self-video feedback on the eyedrop instillation techniques of glaucoma patients: a prospective randomized controlled trial

Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde